Exploring molecular abnormalities in cancer
Research type
Research Study
Full title
Identifying and testing the clinical value of molecular abnormalities in cancer, including non-invasive circulating molecular diagnostics, disease-monitoring and prognostication
IRAS ID
282883
Contact name
Matthew Murray
Contact email
Sponsor organisation
University of Cambridge
Clinicaltrials.gov Identifier
HVS/2019/2940, Insurance
Duration of Study in the UK
9 years, 11 months, 30 days
Research summary
This study will use existing human tissue and circulating samples, and relevant primary cell lines, to study the biological effects that lead to and are caused by human cancers. The project will study molecular changes, cellular alterations and the effects of manipulating the cellular machinery to either prevent or to induce cancerous changes in cells. Human tissue will be used to extract DNA, RNA and protein and to observe the changes in the cells that occur due to human cancers compared with normal tissue. Circulating samples, including from tissue banks and clinical trials, will be used to study if the same molecular changes seen in the cancer tissues can be found at diagnosis, can be used for disease-monitoring and for prognostication (predicting outcome).
REC name
London - Bromley Research Ethics Committee
REC reference
20/PR/0126
Date of REC Opinion
7 Jul 2020
REC opinion
Favourable Opinion